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We report a case of a 37-year-old man with metastatic differentiated thyroid carcinoma, previously sub-
mitted to total thyroidectomy, radio-iodine therapy and lung metastasectomy, who underwent systemic
treatment with lenvatinib for tumor recurrence in the lung, mediastinal lymph nodes, left gluteus and
left orbit. Lenvatinib induced rapid and durable disease regression; the drug effect has continued after
>1 year, as well as a very considerable clinical benefit. The results achieved by lenvatinib in treatment
of metastatic differentiated thyroid carcinoma are clear and irrefutable. Real-life data, obtained by case
reports and retrospective studies, are equally important to increase the knowledge about this drug and
improve the clinical management.
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Differentiated thyroid carcinoma (DTC) is the most common malignant tumor of the thyroid gland. Although
the incidence of this cancer has been increasing over the last few decades, mortality is constantly decreasing, owing
mainly to improvements in early diagnosis and local treatment [1]. In fact, low-stage disease, which is amenable
to surgical resection, has excellent prognosis [2]. Post-surgical radioiodine (131I) therapy is not generally indicated
in T1 and T2 stages even though it could be considered in case of presence of other risk factors (more aggressive
histological types, positive lymph nodes, history of exposure to radiation) [3]. 131I therapy is generally recommended
for adjuvant treatment for T3 and T4 patients, with the aim of reducing the risk of disease relapse [4]. Distant
metastatic spread occurs in aminority of cases (approximately 10%), with lung and bones being themost commonly
involved sites. Thyroid cancer that relapses during or after adjuvant 131I therapy carries a poor prognosis because
of refractoriness to conventional anticancer treatments. Historically, surgical resection of metastases and external
beam radiotherapy, when feasible, has represented suitable treatment options. Increased knowledge in the molecular
biology of thyroid cancer has clarified the complex signaling networks that sustain this cancer phenotype. These
involve angiogenesis, BRAF, NRAS, HRAS, RET/DTC, FGFR and PDGFR signaling. As a consequence, a strong
rationale supported the clinical evaluation of multitargeted tyrosine kinase inhibitors (TKIs). One of these agents,
sorafenib, was investigated in a randomized Phase III trial that included 417 patients, where it resulted superior
to placebo in terms of progression-free survival (PFS; 10.8 vs 5.4 months) [5]. More recently, lenvatinib, an oral
multitargeted TKI that inhibits VEGFR1–3, PDGFR-α, FGFR1–4, RET and KIT – all targets implicated in
signaling networks that promote angiogenesis [6] – was approved on the basis of a Phase III trial enrolling 360
patients with iodine-refractory thyroid cancer, who were randomized to lenvatinib 24 mg/day or placebo. PFS was
significantly higher in lenvatinib group (median PFS: 18.2 vs 3.6 months, hazard ratio: 0.21; 99% CI: 0.14–0.31;
p < 0.001), although no advantage in overall survival was observed [7]. Based on these results, lenvatinib was
approved for the treatment of patients with radioiodine-refractory metastatic DTC (MDTC). Here, we report
the case of a young patient with MDTC treated with lenvatinib after total thyroidectomy, 131I therapy and lung
metastasectomy. The patient achieved a long-term response on all sites of metastasis and a very important clinical
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benefit with complete resolution of all symptoms. The collection of clinical cases concerning this uncommon
neoplasm could help the clinicians in the management of daily practice.
Presentation of case
A 37-year-old man underwent total thyroidectomy in October 2013 because of the incidental finding of a thyroid
lesion. Histological examination showed a papillary carcinoma, staged T3Nx, according to the seventh edition of
Tumor, Node, Metastasis staging. No distant metastases were detected by total body CT scan. Because of the high
stage, the patients received an adjuvant therapy with 131I (0.7 μg/kg/day in 3 days). The post-131I CT-scan showed
no residual disease and the follow-up was unremarkable until September 2015 when a routine blood test revealed an
increase in the levels of high-sensitivity human thyroglobulin. The 18-fluorodeoxyglucose (18-FDG) PET CT scan
showed significant radiotracer uptake in the right lung. In November 2015, the patient underwent resection of the
lung lesions, with histopathological examination confirming metastatic thyroid cancer, with oxyphil cells and low
differentiated features. Based on no other clear evidence of distant metastases after surgical resection, the patient
resumed regular clinical follow-up. In May 2016, multiple bilateral lung lesions were detected by a routine total
body CT scan. Considering the small size of the new nodules and the absence of symptoms, the treating physician
opted for a wait-and-see approach. Repeat CT scans revealed no signs of progression until March 2017, when,
in spite of stable numerical and dimensional disease in the lung, a new 16-mm nodule was detected in the right
kidney. Concomitantly, the patient presented with pain in left gluteus muscle, diplopia and vision impairment of
the left eye. A CT scan of the head showed thickening of medial rectus muscle, with deviation and compression of
homolateral optical nerve. An 18-FDG PET-CT scan revealed pathological uptake in left orbit, in the mediastinal
lymph nodes and in the left gluteus, confirming the clinical suspicion of disease progression. A multidisciplinary
evaluation was performed, and it was decided to treat the patient with radiotherapy to the right retrobulbar space.
This consisted of 44 Gy administered in 22 fractions, from June to July 2017, with a partial benefit on visual
symptoms. In August 2017, systemic therapy with lenvatinib was started. The patient received the recommended
dose of 24 mg daily and underwent clinical and laboratory evaluation initially every 2 weeks for 2 months, and
subsequently every month. Arterial blood pressure, physical examination, serum chemistry and hematology were
evaluated at each visit. Serum thyroid hormone concentration, ECG and echocardiogram were repeated every 3
months. The first CT scan performed in October 2017, showed partial response of disease in all sites of metastases.
However, the full dose of lenvatinib was not well tolerated, in particular, in terms of recurrent grade 3 hypertension,
according to the common terminology criteria for adverse events version 4.03. According to the insert package,
the drug was reduced to 20 mg daily with no subsequent recurrence of clinically relevant hypertension. Cardiac
and thyroid functions remained within in the normal range. Patient symptoms, including visual disturbances that
had remained after radiotherapy, resolved completely within the first 6 months of treatment with lenvatinib. The
3-monthly follow-up CT scans showed no signs of disease progression. The following CT scans, performed every
3 months, showed no signs of disease progression, and even a progressive reduction of all sites of metastases. The
last CT scan, performed in early May 2019, confirmed this trend, showing an additional response of all sites of
metastases. At more than 22 months from the start of systemic therapy, the patient is asymptomatic and with no
major treatment-related side effects.
Discussion & conclusion
Multitargeted TKIs represent a relevant therapeutic option for patients with iodine-resistant metastatic DTC, a
condition that had very limited therapeutic options before the advent of these drugs [5–7]. By targeting multiple
pathways that underlie this cancer phenotype, lenvatinib has confirmed a remarkable effect on PFS, compared
with placebo, in a large randomized clinical trial [7]. Off-target activity, which represents the downside of these
drugs, has resulted in a spectrum of side effects that should account for when deciding when and how to use this
drug in the clinical practice. Indeed, based on the results of the pivotal trial, about six out of ten patients are
expected to show disease response and median duration of response is 30 months, which translates in very long
drug exposure in the majority of treated patients [8]. The case that we discuss here is interesting for a number of
practical reasons. First, the drug induced rapid disease regression, as revealed by improvement in related disease
symptoms (gluteal pain) and radiological evidence. One of the first aims of the treatment of metastatic disease is
symptom palliation and, in this case, further improvement occurred in the initial months of treatment, leading to
complete and long-lasting resolution of patient initial complaints. Second, the patient has been on treatment for
more than 1 year now and, except for the initial 2 months, he now undergoes monthly visits to check tolerance
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and toxicity. Indeed, management of toxicities is an important issue, treatment is to be continued until disease
progression and the quality of life is an essential end point to consider. Multitargeted TKIs are generally associated
with several adverse effects, including hypertension, oral mucositis, fatigue, increased risk of thromboembolism,
hepatotoxicity, skin changes, nausea, diarrhea, anorexia and thyroid function alteration [9]. For this reason, an
adequate follow-up of these patients in order to introduce the opportune countermeasures when necessary is
fundamental. These potential side effects may negatively impact the quality of life, resulting frequently in dose
reduction or treatment discontinuation. In the case, we described here, only a dose reduction from 24 to 20 mg/day
was necessary when grade 3 hypertension occurred, with no further recurrence of this side effect. The clinical benefit
was particularly interesting, especially concerning the ocular symptoms. The patient developed a metastasis in the
orbital cavity, which affected his sight, producing diplopia and reduction of visual acuity. As described above, this
lesion was treated with radiotherapy according to standard of care. Residual sight impairment resolved completely
during systemic therapy with lenvatinib. Concomitantly, pain reported at the start of lenvatinib therapy and that
required analgesic disappeared after approximately 1 month of treatment, with consequent withdrawal of pain
medications. One final point emerges from this clinical case, which – due to the efficacy of lenvatinib – should
not be considered ‘anecdotal’ but yet a frequent occurrence. Our patient underwent surgical treatment of the first
metastatic occurrence and local therapy to a critical orbital lesion. These two options, although not devoid of
potential complications, have always been considered the standard of care in the absence of active systemic drugs.
Nowadays, with the availability of drugs yielding high response rate and long-lasting disease control, the question
is – what is the role of local therapy in the management of metastatic DTC? In our opinion, it could be reasonable
to treat this disease upfront with lenvatinib or with similar drugs that will show comparable or increased efficacy in
the future, reserving surgery or radiation therapy either for resistant disease or for particular situations (medullary
compression and oligometastatic progression). However, it should be noted that even this approach, although it
could be reducing the local treatment related comorbidities, is not without limitations. For example, the upfront
strategy requires a lifelong therapy, which could be impaired the patients’ quality of life. Furthermore, in case
of TKI-refractory disease, the upfront approach would leave very few treatment options. Then, even though the
systemic therapy in DTC is generally effective and well tolerated, the treatment strategy should be planned by a
multidisciplinary team, on a case-by-case basis.
In conclusion, the results achieved by lenvatinib in treatment of MDTC are clear and irrefutable. Real-life data,
obtained by case reports and retrospective studies, are equally important to increase the knowledge about this drug
and improve the clinical management. The optimal approach to thyroid cancer remains multidisciplinary, involving
surgeons, radiation therapists, endocrinologists and oncologists, but due to the availability active systemic drugs,
such as lenvatinib, current treatment paths should be redesigned.
Summary points
• Differentiated thyroid carcinoma (DTC) is the most common thyroid cancer.
• Metastatic disease is rare, but not occasional.
• Metastatic disease has few treatment options.
• Lenvatinib showed great efficacy in metastatic DTC.
• A 37-year-old man with DTC was described.
• Lenvatinib therapy was performed.
• The patient was responding to lenvatinib for 22 months.
• The patient noticed a very important quality of life improvement.
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